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The Structural Biology laboratory at NASA Marshall Spaceflight
Center uses x-ray crystallographic techniques to conduct research
into the three-dimensional structure of a wide variety of proteins.
A major effort in the laboratory involves an ongoing study of human
serum albumin (the principal protein in human plasma) and its
interaction with various endogenous substances and pharmaceutical
agents. Another focus is on antigenic and functional proteins from
several pathogenic organisms including the human immunodeficiency
virus (HIV) and the widespread parasitic genus, Schistosoma. My
efforts this summer have been twofold: first, to identify clinically
significant drug interactions involving albumin binding displacement
and to initiate studies of the three-dimensional structure of
albumin complexed with these agents, and secondly, to establish
collaborative efforts to extend the lab's work on human pathogens.
ALBUMIN STUDIES
Human serum albumin (HSA) is the most abundant of the plasma
proteins with an average concentration in healthy individuals of 5 gm/dl. It is
important in maintaining the colloid oncotic pressure and in binding an
enormous variety of endogenous and exogenous ligands. Binding to HSA
greatly increases the solubility of fatty acids and bilirubin in the plasma.
Albumin also binds amino acids, steroids, and several metals and is implicated
in the facilitated transfer of many ligands across organ-circulatory interfaces. By
complexing with various pharmaceutical agents, albumin can strongly influence
their therapeutic effect. In some cases, this may render agents inactive in vivo
despite high efficacy in the absence of albumin in vitro.
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Human albumin consists of 585 amino acids, has a molecular weight of
66,500 daltons, and contains 17 disulfide bridges. There
Drugs displaced from albumin in clinically important interactions tend to
have a small volume of distribution, a low therapeutic index, and undergo
restrictive elimination. 10 Compounds which are present in high concentrations
and are tightly protein bound such as non-steroidals, valproic acid, and
sulfamethoxazole are particularly capable of displacing other agents and must
be used with caution when they are given concomitantly. 14
Efforts have begun to determine the three dimensional structure of
albumin complexed with various compounds which are involved in clinically
significant displacement interactions. Crystals of HSA bound to phenytoin,
valproic acid, sulfamethoxazole, and tolbutamide have been grown from
polyethylene glycol using the hanging drop and sitting drop techniques as
previously described. 1 Ceftriaxone bound albumin will be crystallized in the
near future. The crystals are to be used in x-ray diffraction studies to determine
the three dimensional molecular structures of the albumin-ligand complexes.
X-ray diffraction data collection has already begun on albumin bound to
valproic acid, phenytoin, and sulfamethoxazole. Initial difference mapping
indicates that valproic acid attaches in the IliA binding site.
COLLABORATIVE STUDIES
Efforts have been made to establish collaborations which will expand the
work of the Structural Biology Laboratory in the study of human pathogens.
Schistosomiasis, a parasitic disease endemic in Africa, South America, and
Asia, historically has been one of the most significant causes of morbidity and
mortality in the world. The parasite, which is absorbed through the skin from
contaminated water, is a blood fluke which, in its various forms, may cause liver
and spleen enlargement, hepatic fibrosis, portal hypertension, diarrhea, and
cystitis, as well as pulmonary and CNS symptoms. Although a highly
efficacious curative agent is now available (praziquantal), disease control has
proven very difficult because of high reinfection rates. Therefore, worldwide
efforts have focused on the development of a vaccine, but none is yet available.
Previous studies by the Structural Biology Lab resulted in the determination of
the three-dimensional structure of the 26 kDa glutathione S-transferase from
Schistosoma japonicum. 18 Glutathione transferase has been identified by
other investigators as a possible vaccine candidate for both S japonicum and S
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mansonL 19 However, schistosomes posses two glutathione transferases, and
a successful vaccine would probably require an immune response to both.
Therefore, it is desirable that the 28 kDa GST from S japonicum and both
GSTs from S mansoni be studied crystallographically. The laboratory of Dr.
Kathy Davern at the Walter and Eliza Hall Institute for Medical Research in
Melbourne, Australia has a long history of successful studies of schistosomal
GSTs. Dr. Davern has agreed to produce these proteins by recombinant
techniques and supply them to NASA as part of a collaborative agreement
reached this summer. Work has already begun on the protein production, and
the GSTs are expected to be available for crystallization and structural studies
within approximately six weeks.
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